Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Alpa LaboratoriesNSE:ALPA -2.40%76 Debt-to-EBITDA is 0.18 as of Mar. 2026, which is at its 10-year median of 0.18. GuruFocus rates NSE:ALPA with a GF Score™ of 76/100 and a GF Value™ of ₹93.32 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 681 Drug Manufacturers companies, Alpa Laboratories ranks better than 84.43% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Alpa Laboratories's Debt-to-EBITDA or its related term are showing as below:
NSE:ALPA'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0 Med: 0.18 Max: 1.07
Current: 0.13
During the past 13 years, the highest Debt-to-EBITDA Ratio of Alpa Laboratories was 1.07. The lowest was 0.00. And the median was 0.18.
NSE:ALPA's Debt-to-EBITDA is ranked better than 84.43% of 681
companies
in the Drug Manufacturers industry
Industry Median: 1.62
vs NSE:ALPA: 0.13
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Alpa Laboratories Debt-to-EBITDA Related Terms
Alpa Laboratories Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Alpa Laboratories's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Alpa Laboratories's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alpa Laboratories Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Alpa Laboratories's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Alpa Laboratories's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Alpa Laboratories (NSE:ALPA) has a Debt-to-EBITDA of 0.18 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Alpa Laboratories. This is near median its historical median of 0.18. According to the industry distribution chart, Alpa Laboratories ranks #106 out of 681 companies in the Drug Manufacturers industry, placing it in the top 15.6%.
Is Alpa Laboratories' Debt-to-EBITDA too high?
Alpa Laboratories' current Debt-to-EBITDA of 0.18 is near median its 10-year median of 0.18. The Drug Manufacturers industry median Debt-to-EBITDA is 1.62. Alpa Laboratories' value of 0.18 is 88.9% below this industry median. Based on the distribution chart, Alpa Laboratories ranks #106 out of 681 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Alpa Laboratories has a GF Score™ of 76/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Alpa Laboratories' Debt-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Alpa Laboratories ranks #106 out of 681 companies for Debt-to-EBITDA. This places Alpa Laboratories in the top 16% of its industry — outperforming the majority of peers. The industry median Debt-to-EBITDA is 1.62. Alpa Laboratories' value of 0.18 is 88.9% below this benchmark. While the company's 10-year median is 0.18 vs. the industry median of 1.62, Alpa Laboratories has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.62, based on 681 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alpa Laboratories's current Debt-to-EBITDA of 0.18 is 88.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Alpa Laboratories. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alpa Laboratories's current Debt-to-EBITDA is 0.18, which is near median its own 10-year median of 0.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alpa Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Alpa Laboratories (NSE:ALPA) is currently considered Possible Value Trap. The stock's GF Value™ is ₹93.32, compared to a current price of ₹64.27 — trading 31.1% below its estimated fair value. The current Debt-to-EBITDA is 0.18, which is near median its 10-year median of 0.18 and 88.9% below the Drug Manufacturers industry median of 1.62. Alpa Laboratories' overall GF Score™ is 76/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Alpa Laboratories (NSE:ALPA), the current Debt-to-EBITDA is 0.18 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alpa Laboratories (NSE:ALPA) Overvalued in 2026?
Based on GuruFocus' analysis, Alpa Laboratories stock appears to be undervalued.
The current stock price of ₹64.27 is trading 31.1% below its estimated GF Value™ of ₹93.32.
GuruFocus considers Alpa Laboratories to be Possible Value Trap.
Key valuation signals for NSE:ALPA:
Debt-to-EBITDA: 0.18 (near median its 10-year median of 0.18)
GF Value™: ₹93.32 vs. price of ₹64.27 (31.1% below fair value)
Industry Position: 88.9% below the Drug Manufacturers median (#106 of 681)
No single metric tells the full story. See the NSE:ALPA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alpa Laboratories Ltd is an India-based pharmaceutical company. It operates in the drug and chemical business segment. The company manufactures and markets pharmaceuticals and related products. It sells products like liquid injection, dry powder injection, tablets, capsules, and ointments.
76GF Score
Get the complete analysis for NSE:ALPA
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ALPA has been successfully added to your 
